ROS1ders Blog

ROS1 fusions, ROS1+ cancer, and entrectinib

Why Did My TKI Stop Working? Targeted Therapy and Acquired Resistance

What is Entrectinib (Rozlytrek)? How it Works, Side Effects and More

What is Targeted Therapy?

Confused about 1st and 2nd line drugs? Here’s a guide!

The ROS1ders Interview Dr. Ross Camidge

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

ROS1 News From Europe

Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors

Thinking about a “drug vacation” from crizotinib? Read this first!

Crizotinib approved for ROS1 in Australia

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

Crizotinib may be effective again after chemo

TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP

Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)